Repligen Company (NASDAQ: RGEN) today announced the pricing of an underwritten public offering at a public offering price of $181 per share for 1.5 million shares of its common stock.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Sponsored
Repligen Company has also given the underwriters a 30-day chance to buy up to 225,000 additional common stock securities, fewer discounts, and commissions at the public bidding offer. Repligen estimates the revenue from the offering to be roughly around $271.5 million before deducting the underwriting discounts and fees and other offering costs, minus any exercise of the underwriters’ choice to buy additional stock. Subject to standard closing terms, the offering is scheduled to close on or around 10 December 2020.
A Backdoor Way To Profit From Today’s Crypto Bull Market
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Sponsored
Repligen Company plans to use the net proceeds from this sale for working capital and other general corporate needs. Net profits from this deal can also be used to support future sales or acquisitions in supplementary entities, goods, facilities, and technology. At this time, Repligen has not entered into any agreements or commitments about any acquisitions or investments.
These shares will be offered and distributed in compliance with the Securities and Exchange Commission (S.E.C.) and an immediately effective declaration of the shelf’s registration (including the base prospect), which had been previously submitted. A preliminary supplement to the prospectus related to this bid was submitted with the S.E.C. If available, copies of the final supplement to the prospectus and the accompanying prospectus relating to this offering can be obtained from J.P. Morgan Securities L.L.C.
Repligen Corporation is a global life sciences organization that produces and commercializes very advanced bioprocessing technologies and systems that improve biological drug production processes’ performance. Biopharmaceutical device manufacturers and contract production and processing companies (CDMOs) worldwide are our main clients.
